Press Releases

Date Title and Summary Additional Formats
Toggle Summary NewLink Updates Enrollment Information for Its Pivotal Phase 3 HyperAcute(R) Pancreas Immunotherapy (algenpantucel-L) Trial
AMES, Iowa , June 19, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK) today announced that in the second quarter of 2012 it passed the midpoint in enrollment in its Phase 3 HyperAcute Pancreas immunotherapy product candidate (algenpantucel-L) trial as number of participating
View HTML
Toggle Summary Interferon-y (IFN-γ) response correlates with survival in a Phase 2 Hyperacute (tergenpumatucel-L) immunotherapy trial for non-small cell lung cancer (NSCLC) View HTML
Toggle Summary Data From Phase 1 and Phase 1B Studies of NewLink Genetics' IDO Pathway Inhibitor (NLG8189) Presented at 2012 ASCO Annual Meeting
NLG8189 Demonstrates Good Safety Profile and Bioavailability With Early Evidence of Activity
View HTML
Toggle Summary NewLink Genetics HyperAcute® Lung (tergenpumatucel-L) Immunotherapy Demonstrates a Correlation Between Immune Response and Survival in Patients With Non-Small Cell Lung Cancer
NewLink Genetics HyperAcute® Lung (tergenpumatucel-L) Immunotherapy Demonstrates a Correlation Between Immune Response and Survival in Patients With Non-Small Cell Lung Cancer AMES, Iowa, June 4, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq: NLNK ) announced its HyperAcute® Lung
View HTML
Toggle Summary NewLink Genetics Reports Two- and Three-Year Overall Survival Data From Its Phase-2 HyperAcute® Pancreas (algenpantucel-L) Immunotherapy Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
AMES, Iowa, June 4, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq: NLNK ) announces that its HyperAcute® Pancreas (algenpantucel-L) Immunotherapy will be featured today in a poster presentation (abstract number 4049) at the American Society of Clinical Oncology (ASCO) 2012 Annual
View HTML
Toggle Summary Addition of algenpantucel-L immunotherapy to standard of care (SOC) adjuvant therapy for pancreatic cancer View HTML
Toggle Summary Data From an Investigator-Initiated Phase 2 Study of NewLink Genetics' HyperAcute® Melanoma Immunotherapy Published in 2012 ASCO Annual Meeting Abstracts
HyperAcute Melanoma Demonstrates Activity in Stage III and Stage IV Patients
View HTML
Toggle Summary NewLink Genetics to Present at the Jefferies 2012 Global Healthcare Conference
AMES, Iowa, May 30, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics (Nasdaq:NLNK) announced today that Dr. Charles Link, Chairman and Chief Executive Officer, will present at the Jefferies 2012 Global Healthcare Conference in New York on Wednesday, June 6, 2012, at 4:30 p.m. (EDT). Dr.
View HTML
Toggle Summary Data From NewLink Genetics Phase 2 Trial of Its HyperAcute(R) Pancreas (Algenpantucel-L) Immunotherapy to be Presented at the 2012 Digestive Disease Week
Algenpantucel-L Immunotherapy Phase 2 Data Featured in Plenary Session at 53rd Annual Meeting of the Society for Surgery of the Alimentary Tract and Will be Published in the Journal of Gastrointestinal Surgery
View HTML
Toggle Summary NewLink Genetics Corporation Reports First Quarter 2012 Financial Results
AMES, Iowa, May 10, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today reported consolidated financial results for the first quarter of 2012, and provided an update on the
View HTML